Growth hormone does not affect albumin synthesis in the critically ill.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 11430539.
- Also identified by PMC identifier 7095101.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To study the effect of growth hormone (GH) on albumin synthesis in critically ill patients. Prospective randomized controlled study. Two intensive care units, university hospital and county hospital, respectively. Twenty-two critically ill patients in the intensive care unit. Albumin synthesis was measured twice in each patient, with a 5-day interval. The patients in the control group (n = 11) received standard intensive care unit (ICU) treatment between measurements, whereas those in the GH group (n = 11) also received 0.3 U/kg daily of human recombinant GH. Albumin synthesis was measured by labeling with L-[2H5]phenylalanine. In the control group, the fractional synthesis rate (FSR) of albumin was 16.3+/-4.1%/day (mean and SD) in the first measurement and 15.7+/-4.2%/day 5 days later (NS), whereas in the GH group the corresponding values were 17.0+/-4.7%/day and 16.7+/-5.5%/day (NS). The calculated absolute synthesis rates of albumin, based on FSR and intravascular albumin mass, also showed no effect of GH. Albumin synthesis rates were consistently higher in the two groups of critically ill patients than previously reported values in healthy subjects. However, GH treatment for 5 days neither stimulated nor inhibited albumin synthesis rates in these critically ill patients.
Medical subject headings
- Growth Hormone
- Serum Albumin